HOME >> MEDICINE >> NEWS
Enoxaparin beats unfractionated heparin as adjunct therapy for heart attacks

cardial Infraction. (ExTRACT-TIMI 25) study led by the TIMI Study Group (Boston).

"Based on the results of the ExTRACT-TIMI 25 trial, we believe that a strategy using enoxaparin is now the preferred anticoagulant regimen in heart attack patients who receive clot-busting drugs," said Eugene Braunwald, M.D., M.A.C.C., Distinguished Hersey Professor of Medicine, Harvard Medical School, Chairman, TIMI Study Group, Brigham and Women's Hospital.

Researchers found that enoxaparin reduced the combined risk of death and MI within 30 days by 17 percent. Similarly, enoxaparin reduced the 30-day risk of nonfatal repeat MI by 33 percent, and the 30-day combined risk of death, nonfatal MI, and urgent need to re-establish blood flow to the heart by 19 percent. All of the findings were highly statistically significant.

The trial enrolled 20,506 patients from 674 medical centers in 48 countries. All patients had ST-elevation MI (STEMI), a serious form of heart attack characterized by elevation of the "ST segment" on the electrocardiogram. They were treated with a fibrinolytic, or clot-busting, medication within six hours of first experiencing chest pain, and were then randomly assigned to receive therapy with enoxaparin or unfractionated heparin.

To make sure there was no unintended bias in interpreting the results, the trial used a double-blind, double-dummy design: study participants received both intravenous infusions and twice-daily injections without the physician or the patient knowing which contained the study medication and which was the placebo.

The rates of serious bleeding were lower overall than reported in prior trials. Patients who were treated with the enoxaparin strategy were more likely to experience major bleeding. However, when researchers calculated net clinical benefit, which takes into account both effectiveness and safety, the enoxaparin strategy was, on balance, associated with significantly better outcomes.
'"/>


14-Mar-2006


Page: 1 2 3

Related medicine news :

1. US beats Europe for hypertension treatment
2. For super-obese patients, duodenal switch beats gastric bypass
3. Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder
4. New data demonstrate effectiveness of LAMICTAL (lamotrigine) as adjunctive therapy
5. Chemotherapy with bevacizumab increases risk of blood clots in arteries
6. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
7. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
8. Hormone therapy offers new hope for ovarian cancer patients
9. Borderline personality disorder shows improvements with intensive psychotherapy
10. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
11. Chemotherapy may enhance the effectiveness of brain tumor vaccines

Post Your Comments:
(Date:4/1/2015)... BioPlus Specialty Pharmacy (BioPlus), ... released a new app to keep health care providers ... hepatitis C virus (HCV) infection. This ‘HCV Treatment Path’ ... the American Association for the Study of Liver Diseases ... direct-acting oral medications to treat HCV have been approved ...
(Date:4/1/2015)... Dr. Daniel C. Stewart will be ... the benefits of the LANAP® treatment over traditional ... People who live in Howard County, and surrounding areas ... visit Dr. Stewart, a Maryland dentist, for a minimally ... protocol, which is a laser gum surgery procedure, Dr. ...
(Date:4/1/2015)... 2015 OSF Saint Paul Medical Center, ... , was welcomed into the Ministry April 1, 2015, ... Paul E. Showalter, vicar general of the Catholic Diocese ... culminated a nearly year-long transition process for the former ... Speakers for the morning ceremony included Sister Judith Ann ...
(Date:4/1/2015)... 01, 2015 Aging2.0 , the ... announces the launch of the Aging2.0 Alliance ... stakeholders and technology companies. The announcement was made today ... and Business Strategies Forum in San Diego, CA. ... Alliance program is now open for additional members. “This ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , ... of the Department of Plastic Surgery at UT Southwestern ... reports of blindness resulting from the use of ... published their study, along with ideas for treatment and ... "We began to see increasing reports of blindness as ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3
(Date:4/1/2015)... April 1, 2015   Advocates for Responsible Care ... health care professionals, patient advocates and human rights ... which will go live at 9:00 a.m. today. ... in Reach is a new campaign to limit rising ... families. Led by Advocates for Responsible Care, in partnership with ...
(Date:4/1/2015)... NEW YORK , April 1, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming HIMSS 2015 Conference. The conference ... Chicago , from April 12 through 16. In ... at their respective booths, AMC Health will share innovations ...
(Date:4/1/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... industry veteran, Erich Mohr , Ph.D., R.Psych., to ... Dr. Mohr has close to two decades of ... scientific officer, chief executive officer and board member, including ...
Breaking Medicine Technology:'Rx in Reach' Campaign Launches in Georgia 2'Rx in Reach' Campaign Launches in Georgia 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 2AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 4DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 2DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 3DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 4
Cached News: